Kesmalea Therapeutics
- Biotech or pharma, therapeutic R&D
Kesmalea is developing orally available, CNS penetrant targeted protein degraders. We are backed by Syncona and OSE.
Kesmalea’s SELFTAC® platform is a widely applicable solution to the “size problem” of traditional bifunctional degraders. We insert a reversible linker between the two main components of these large degraders, transforming them into small molecules that self-assemble into the bifunctional degrader at the appropriate location to fight disease. As small molecules, their oral bioavailability and ability to penetrate the central nervous system is much easier to achieve.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}